Fluconazole resistance has become an important problem in the management of HIV-infected patients with recurrent oropharyngeal candidiasis (OPC). Fluconazole resistance can develop in a persistent strain or from emergence of a new resistant strain. Cross-resistance to other antifungals is common. Molecular mechanisms of fluconazole resistance include alterations in the target enzyme, increased efflux of drug mediated by two types of multidrug pumps, and changes in plasma membrane sterols. The prevalance of these mechanisms and the correlation between mechanisms of resistance and antifungal management strategies has not been determined. The use of highly active retroviral therapy has reduced the incidence of oropharyngeal candidiasis in some patients, but the impact of antiretroviral therapy on recurrence of infection and specific mechanisms of resistance is not known. Thus, the objectives of this proposal are to investigate the molecular epidemiology of antifungal resistance in oropharyngeal candidiasis and to correlate efficacy of antifungal therapy with mechanisms of resistance. These objectives will be achieved through the unique opportunity to analyze mechanisms of resistance in a collection of over 4,500 yeast isolates collected prospectively from over 291 episodes of thrush in 64 patients serially evaluated.
The specific aims of this proposal are: 1) to evaluate the impact of highly active antiretroviral therapy on oropharyngeal candidiasis and to determine the efficacy of high dose fluconazole in oropharyngeal candidiasis due to yeasts with decreased susceptibility in order to establish the effect of therapeutic strategies on development of resistance; 2) to determine the epidemiology of molecular mechanisms of resistance in oropharyngeal candidiasis and to assess the correlation between resistance mechanisms and antifungal management strategies and response to treatment; and 3) to characterize molecular resistance mechanisms in selected clinical isolate without known resistance mechanisms, assess the correlation between treatment strategies and resistance mechanisms, and ultimately result in improved management of patients with oropharyngeal candidiasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
2R01DE011381-04A2
Application #
6080503
Study Section
Special Emphasis Panel (ZRG1-AARR-4 (01))
Program Officer
Mangan, Dennis F
Project Start
1994-09-30
Project End
2003-02-28
Budget Start
2000-03-01
Budget End
2001-02-28
Support Year
4
Fiscal Year
2000
Total Cost
$251,848
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Patterson, Thomas F (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013-25
Bachmann, Stefano P; Ramage, Gordon; VandeWalle, Kacy et al. (2003) Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother 47:3657-9
Redding, Spencer W; Kirkpatrick, William R; Saville, Stephen et al. (2003) Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol 41:619-22
Martinez, Marcos; Lopez-Ribot, Jose L; Kirkpatrick, William R et al. (2002) Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 40:3135-9
Bachmann, Stefano P; Patterson, Thomas F; Lopez-Ribot, Jose L (2002) In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40:2228-30
Perea, Sofia; Lopez-Ribot, Jose L; Wickes, Brian L et al. (2002) Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 46:1695-703
Martinez, M; Lopez-Ribot, J L; Kirkpatrick, W R et al. (2002) Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 49:515-24
Perea, Sofia; Gonzalez, Gloria; Fothergill, Annette W et al. (2002) In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 46:3039-41
Bachmann, Stefano P; VandeWalle, Kacy; Ramage, Gordon et al. (2002) In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 46:3591-6
Redding, S W; Bailey, C W; Lopez-Ribot, J L et al. (2001) Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91:659-62

Showing the most recent 10 out of 28 publications